<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04649138</url>
  </required_header>
  <id_info>
    <org_study_id>2017/981</org_study_id>
    <nct_id>NCT04649138</nct_id>
  </id_info>
  <brief_title>Fomepizole Dosing During Continuous Renal Replacement Therapy (CRRT)</brief_title>
  <official_title>Fomepizole Dosing During Continuous Renal Replacement Therapy (CRRT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Louisiana State University Health Sciences Center Shreveport</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <brief_summary>
    <textblock>
      The project is a prospective observation study of patients with suspected or confirmed toxic&#xD;
      alcohol poisoning treated with fomepizole and continuous renal replacement therapy (CRRT)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 13, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Measure minimum plasma concentration of fomepizole</measure>
    <time_frame>through study completion, up to 72 hours</time_frame>
    <description>Plasma samples will be obtained up to every hour and before fomepizole is given</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Continuous renal replacement therapy (CRRT) clearance of fomepizole</measure>
    <time_frame>through study completion, up to 72 hours</time_frame>
    <description>Plasma and dialysat samples will be obtained up to every hour</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine saturation/sieving coefficient of fomepizole</measure>
    <time_frame>through study completion, up to 72 hours</time_frame>
    <description>Plasma and dialysat samples will be obtained up to every hour</description>
  </secondary_outcome>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Toxic Alcohol Poisoning</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Toxic alcohol poisoning treated with fomepizole and CRRT.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients (over 18 year) with suspected or confirmed toxic alcohol poisoning treated&#xD;
             with fomepizole and CRRT.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who wish to withdraw from the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Knut Erik Hovda, MD,PhD</last_name>
      <phone>+47 99618356</phone>
      <email>UXKNOV@ous-hf.no</email>
    </contact>
    <contact_backup>
      <last_name>Yvonne Lao, M.Sc.</last_name>
      <email>yvonnela@ous-hf.no</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 30, 2020</study_first_submitted>
  <study_first_submitted_qc>November 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2020</study_first_posted>
  <last_update_submitted>November 24, 2020</last_update_submitted>
  <last_update_submitted_qc>November 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Knut Erik Hovda</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Poisoning</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

